SARM1 Inhibitor and NAD+ Combination for Axonal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Axonal degeneration is a hallmark of neurological disorders and injuries, leading to devastating consequences due to the depletion of NAD+ by SARM1, which triggers rapid axonal degeneration and bioenergetic crisis.
Innovation Solution
Combining NAD+ or its precursors with a SARM1 inhibitor to maintain higher intracellular NAD+ levels, thereby preventing and ameliorating axonal degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If SARM1 is activated to clear damaged axons, then axonal degeneration occurs to remove harmful structures, but NAD+ is depleted causing bioenergetic crisis and rapid axonal death
Solution Approach 1:
The patent applies preliminary anti-action by administering NAD+ or NAD+ precursors before SARM1-mediated NAD+ depletion can cause catastrophic axonal degeneration. This pre-emptive supplementation counteracts the harmful NAD+ depletion effect while allowing SARM1 to continue its protective function of clearing damaged axons.
Solution Approach 2:
The patent converts the harmful NAD+ depletion effect into a beneficial therapeutic opportunity by using the SARM1 activation process itself to identify which axons need clearing, while simultaneously supplementing NAD+ to prevent unwanted bioenergetic crisis in healthy axons. The harmful side effect becomes a diagnostic signal that can be managed.
2Reliability
If SARM1 inhibitor is used to prevent NAD+ depletion, then axonal protection is improved, but the ability to clear damaged axons is reduced
Solution Approach 1:
The patent applies local quality by allowing SARM1 activity to vary spatially - in damaged axons where SARM1 is activated, the natural degeneration process proceeds to clear harmful structures, while in healthy axons, NAD+ supplementation prevents depletion. This creates different functional outcomes in different locations without requiring a global inhibitor.
Solution Approach 2:
The patent uses partial action by providing NAD+ supplementation at levels sufficient to prevent depletion in protected axons but not so high as to completely block SARM1-mediated clearance in damaged axons. This partial intervention allows the system to maintain both protective and clearance functions simultaneously.
3Quantity of substance
If NAD+ supplementation alone is administered, then intracellular NAD+ levels are maintained, but axonal protection is insufficient without SARM1 inhibition
Solution Approach 1:
The patent merges two separate therapeutic approaches - NAD+ supplementation and SARM1 inhibition - into a combination therapy that achieves both NAD+ level maintenance and axonal protection. The synergistic effect of combining these mechanisms provides superior protection compared to either approach alone.
Solution Approach 2:
The patent creates a composite therapeutic regimen combining NAD+ (or precursors) with SARM1 inhibitors, where each component contributes a different protective mechanism. This composite approach leverages both the metabolic support from NAD+ and the enzymatic inhibition from SARM1 blockers to achieve robust axonal protection.
4Reliability
If combination therapy is used to achieve superior axonal protection, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent segments the combination therapy into distinct administrable components - NAD+ or precursors can be given separately from SARM1 inhibitors, allowing for flexible dosing schedules and routes of administration. This segmentation makes the complex combination therapy more manageable and easier to implement clinically.
Data Source
AI summary
The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.